Thrombocytopenia and Tedizolid: A new ally in hematologic patients? Brief literature review and a clinical case

Tedizolid (TDZ) is a second-generation oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens and a favorable hematologic safety profile compared to linezolid (LNZ). This review summarizes current evidence on TDZ pharmacokinetics, pharmacodynamics, and its reduced risk of thrombocytopenia. We also report a clinical case of a hematologic patient treated with TDZ for fasciitis after hematopoietic stem cell transplantation, achieving complete infection resolution without adverse hematologic effects. These findings support TDZ as a valuable therapeutic option in hematologic patients, where treatment choices are often limited by drug-induced cytopenias.